03/25/2026
Novo Nordisk has received a warning letter from the FDA regarding significant violations related to the reporting of serious adverse events associated with its weight-loss and diabetes medications, including Ozempic, Wegovy (semaglutide), and Saxenda (liraglutide).
Key points include:
- **Issue**: The FDA cited Novo Nordisk for failing to promptly report serious adverse events, including deaths, su***des, strokes, and suicidal ideation.
- **Key Violations**: Internal procedures allowed staff to reject or delay reports based on perceived causality, contrary to FDA requirements for mandatory reporting.
- **Inspection Findings**: A 2025 inspection revealed systemic failures at Novo Nordisk’s U.S. headquarters, with multiple serious cases not investigated or submitted in a timely manner.
- **Examples of Unreported/Delayed Cases**:
- Patient deaths linked to semaglutide
- Completed su***de of a depressed patient on semaglutide
- Disabling stroke associated with liraglutide
- Suicidal ideation in a patient on semaglutide
- **Clarification**: The FDA did not determine that these drugs caused the reported events; the letter focuses solely on compliance issues. There are no recalls or new safety alerts, and drug approvals remain unaffected.
- **Novo Nordisk's Response**: The company has updated its procedures, submitted a corrective action plan, retroactively reported the cases, and emphasized that there is “no impact on the quality or safety of our medicines.”
- **Broader Context**: This situation arises amidst tens of millions of prescriptions, with separate large trials indicating that semaglutide is associated with lower all-cause mortality in specific high-risk groups, without a causal link to su***de.
